FK 360
Latest Information Update: 30 May 2001
At a glance
- Originator Fujisawa
- Class Nootropics; Pyrimidines; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 23 Jun 1998 Commercial data has been reviewed by Fujisawa
- 06 Dec 1996 No-Development-Reported for Cerebral infarction in Japan (Unknown route)